Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Den europeiske union - nederlandsk - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - clopidogrelbesilaat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotische middelen - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). het st-segment elevatie acuut myocardinfarct, in combinatie met asa in medisch behandelde patiënten in aanmerking komen voor trombolytische therapie. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. voor meer informatie refereer je naar sectie 5.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Den europeiske union - nederlandsk - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - clopidogrel hydrochloride - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotische middelen - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Clopidogrel / Acetylsalicylic acid Mylan Den europeiske union - nederlandsk - EMA (European Medicines Agency)

clopidogrel / acetylsalicylic acid mylan

mylan pharmaceuticals limited - acetylsalicylic acid, clopidogrel hydrogen sulfate - acute coronary syndrome; myocardial infarction - antitrombotische middelen - clopidogrel/acetylsalicylzuur mylan is geïndiceerd voor de secundaire preventie van atherothrombotic gebeurtenissen bij volwassen patiënten die reeds het nemen van clopidogrel en acetylsalicylzuur (asa). clopidogrel/acetylsalicylzuur mylan is een vaste-dosis combinatie geneesmiddel voor voortzetting van de therapie in:non-st-segment elevatie acuut coronair syndroom (instabiele angina pectoris of een non-q-wave myocardinfarct) met inbegrip van patiënten die een stent plaatsing na een percutane coronaire interventionst segment elevatie acuut myocardinfarct in de medisch behandelde patiënten in aanmerking komen voor trombolytische therapie.

Mama Natura Dento tabl. Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mama natura dento tabl.

schwabe pharma belgium bv-srl - chamomilla d6 15 mg; pulsatilla pratensis d6 15 mg; ferrum phosphoricum d6 15 mg; belladonna d6 15 mg; hepar sulfur d12 15 mg - tablet - belladonna; chamomilla; ferrum phosphoricum; hepar sulphur; pulsatilla pratensis

Mama Natura Dormi tabl. Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mama natura dormi tabl.

schwabe pharma belgium bv-srl - magnesium carbonicum d10 20 mg; zincum valerianicum d12 15 mg; cypripedium pubescens d4 15 mg - tablet - zincum valerianicum; magnesium carbonicum; cypripedium pubescens

Mama Natura Gastro tabl. Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mama natura gastro tabl.

schwabe pharma belgium bv-srl - okoubaka aubrevillei d4 20 mg; croton tiglium d6 20 mg; veratrum album d12 20 mg - tablet - croton tiglium; okoubaka aubrevillei; veratrum album

Tears Naturale 1 mg/ml - 3 mg/ml oogdruppels opl. Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tears naturale 1 mg/ml - 3 mg/ml oogdruppels opl.

alcon sa-nv - dextraan 1 mg/ml; hypromellose 3 mg/ml - oogdruppels, oplossing - 1 mg/ml - 3 mg/ml - dextraan 1 mg/ml; hypromellose 3 mg/ml - artificial tears and other indifferent preparations

Mama Natura Tussi siroop Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mama natura tussi siroop

schwabe pharma belgium bv-srl - antimonium sulf. aurant 0,1588 g; bryonia 0,1588 g; drosera 0,1588 g; eucalyptus 0,1588 g; ipecacuanha 0,1588 g - siroop

Reinosan Singer Natura, tabletten 350 mg Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

reinosan singer natura, tabletten 350 mg

singer natura b.v. handelsweg 8 2404 cd alphen aan den rijn - orthosifon blad - tablet - arabische gom (e 414) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; maÏszetmeel, gepregelatineerd ; talk (e 553 b), - datum verstrekking handelsvergunning:01 januari 1901

Temoe Lawak Singer Natura, tabletten Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

temoe lawak singer natura, tabletten

singer natura b.v. handelsweg 8 2404 cd alphen aan den rijn - curcumae amarae rhizoma (ln) ; curcumae aromaticae rhizoma extractum (ln) samenstelling overeenkomend met ; ; curcumae aromaticae rhizoma (ln) ; rhamni purchianae cortex - tablet - aardappelzetmeel, geoxideerd en geacetyleerd ; lactose 1-water ; saccharose ; talk (e 553 b), - datum verstrekking handelsvergunning:01 januari 1901